NASDAQ:PHVS

Pharvaris B.V. Competitors

$25.24
-0.77 (-2.96 %)
(As of 04/20/2021 11:54 AM ET)
Add
Compare
Today's Range
$25.24
Now: $25.24
$26.02
50-Day Range
$25.69
MA: $30.14
$39.23
52-Week Range
$23.06
Now: $25.24
$42.86
Volume200 shs
Average Volume113,413 shs
Market Capitalization$803.64 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Pharvaris B.V. (NASDAQ:PHVS) Vs. SEER, NUVB, IBRX, IMCR, BCAB, and CGEM

Should you be buying PHVS stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Pharvaris B.V., including Seer (SEER), Nuvation Bio (NUVB), ImmunityBio (IBRX), Immunocore (IMCR), BioAtla (BCAB), and Cullinan Oncology (CGEM).

Pharvaris B.V. (NASDAQ:PHVS) and Seer (NASDAQ:SEER) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.

Analyst Ratings

This is a summary of current ratings and price targets for Pharvaris B.V. and Seer, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pharvaris B.V.01302.75
Seer02202.50

Pharvaris B.V. currently has a consensus target price of $47.50, suggesting a potential upside of 82.62%. Seer has a consensus target price of $68.00, suggesting a potential upside of 39.54%. Given Pharvaris B.V.'s stronger consensus rating and higher probable upside, analysts clearly believe Pharvaris B.V. is more favorable than Seer.

Profitability

This table compares Pharvaris B.V. and Seer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pharvaris B.V.N/AN/AN/A
SeerN/AN/AN/A

Valuation and Earnings

This table compares Pharvaris B.V. and Seer's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pharvaris B.V.N/AN/AN/AN/AN/A
SeerN/AN/AN/AN/AN/A

Summary

Pharvaris B.V. beats Seer on 3 of the 3 factors compared between the two stocks.

Nuvation Bio (NYSE:NUVB) and Pharvaris B.V. (NASDAQ:PHVS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, dividends and analyst recommendations.

Profitability

This table compares Nuvation Bio and Pharvaris B.V.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nuvation BioN/AN/AN/A
Pharvaris B.V.N/AN/AN/A

Earnings and Valuation

This table compares Nuvation Bio and Pharvaris B.V.'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation BioN/AN/AN/AN/AN/A
Pharvaris B.V.N/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Nuvation Bio and Pharvaris B.V., as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nuvation Bio00603.00
Pharvaris B.V.01302.75

Nuvation Bio currently has a consensus price target of $17.40, suggesting a potential upside of 63.23%. Pharvaris B.V. has a consensus price target of $47.50, suggesting a potential upside of 82.62%. Given Pharvaris B.V.'s higher probable upside, analysts clearly believe Pharvaris B.V. is more favorable than Nuvation Bio.

Summary

Nuvation Bio beats Pharvaris B.V. on 2 of the 3 factors compared between the two stocks.

ImmunityBio (NASDAQ:IBRX) and Pharvaris B.V. (NASDAQ:PHVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and target prices for ImmunityBio and Pharvaris B.V., as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunityBio00103.00
Pharvaris B.V.01302.75

ImmunityBio currently has a consensus price target of $25.00, indicating a potential upside of 53.56%. Pharvaris B.V. has a consensus price target of $47.50, indicating a potential upside of 82.62%. Given Pharvaris B.V.'s higher possible upside, analysts plainly believe Pharvaris B.V. is more favorable than ImmunityBio.

Profitability

This table compares ImmunityBio and Pharvaris B.V.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunityBioN/AN/AN/A
Pharvaris B.V.N/AN/AN/A

Valuation and Earnings

This table compares ImmunityBio and Pharvaris B.V.'s revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBioN/AN/AN/AN/AN/A
Pharvaris B.V.N/AN/AN/AN/AN/A

Summary

Pharvaris B.V. beats ImmunityBio on 2 of the 3 factors compared between the two stocks.

Pharvaris B.V. (NASDAQ:PHVS) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Valuation & Earnings

This table compares Pharvaris B.V. and Immunocore's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pharvaris B.V.N/AN/AN/AN/AN/A
ImmunocoreN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and target prices for Pharvaris B.V. and Immunocore, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pharvaris B.V.01302.75
Immunocore01202.67

Pharvaris B.V. presently has a consensus price target of $47.50, indicating a potential upside of 82.62%. Immunocore has a consensus price target of $54.3333, indicating a potential upside of 43.36%. Given Pharvaris B.V.'s stronger consensus rating and higher probable upside, analysts clearly believe Pharvaris B.V. is more favorable than Immunocore.

Profitability

This table compares Pharvaris B.V. and Immunocore's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pharvaris B.V.N/AN/AN/A
ImmunocoreN/AN/AN/A

Summary

Pharvaris B.V. beats Immunocore on 3 of the 3 factors compared between the two stocks.

Pharvaris B.V. (NASDAQ:PHVS) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Valuation & Earnings

This table compares Pharvaris B.V. and BioAtla's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pharvaris B.V.N/AN/AN/AN/AN/A
BioAtlaN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Pharvaris B.V. and BioAtla, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pharvaris B.V.01302.75
BioAtla00403.00

Pharvaris B.V. presently has a consensus price target of $47.50, indicating a potential upside of 82.62%. BioAtla has a consensus price target of $58.00, indicating a potential upside of 23.72%. Given Pharvaris B.V.'s higher possible upside, analysts clearly believe Pharvaris B.V. is more favorable than BioAtla.

Profitability

This table compares Pharvaris B.V. and BioAtla's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pharvaris B.V.N/AN/AN/A
BioAtlaN/AN/AN/A

Summary

BioAtla beats Pharvaris B.V. on 2 of the 3 factors compared between the two stocks.

Pharvaris B.V. (NASDAQ:PHVS) and Cullinan Oncology (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Pharvaris B.V. and Cullinan Oncology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pharvaris B.V.01302.75
Cullinan Oncology01302.75

Pharvaris B.V. currently has a consensus price target of $47.50, suggesting a potential upside of 82.62%. Cullinan Oncology has a consensus price target of $48.75, suggesting a potential upside of 51.16%. Given Pharvaris B.V.'s higher probable upside, research analysts clearly believe Pharvaris B.V. is more favorable than Cullinan Oncology.

Valuation and Earnings

This table compares Pharvaris B.V. and Cullinan Oncology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pharvaris B.V.N/AN/AN/AN/AN/A
Cullinan OncologyN/AN/AN/AN/AN/A

Profitability

This table compares Pharvaris B.V. and Cullinan Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pharvaris B.V.N/AN/AN/A
Cullinan OncologyN/AN/AN/A

Summary

Pharvaris B.V. beats Cullinan Oncology on 1 of the 1 factors compared between the two stocks.


Pharvaris B.V. Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
SEER
Seer
1.2$48.23-3.6%$3.04 billionN/A0.00Increase in Short Interest
Gap Up
Nuvation Bio logo
NUVB
Nuvation Bio
2.2$10.43-5.1%$2.18 billionN/A0.00
IBRX
ImmunityBio
1.7$16.66-1.8%$1.85 billionN/A0.00
Immunocore logo
IMCR
Immunocore
1.3$37.86-3.5%$1.69 billionN/A0.00
BioAtla logo
BCAB
BioAtla
1.5$47.47-1.0%$1.61 billionN/A0.00
Cullinan Oncology logo
CGEM
Cullinan Oncology
1.3$32.73-2.0%$1.40 billionN/A0.00Analyst Report
News Coverage
Silverback Therapeutics logo
SBTX
Silverback Therapeutics
1.7$36.30-4.0%$1.32 billionN/A0.00
Nurix Therapeutics logo
NRIX
Nurix Therapeutics
1.9$28.77-1.9%$1.30 billionN/A0.00Analyst Downgrade
EWTX
Cricut
1.1$25.69-4.2%$1.27 billionN/A0.00Analyst Report
News Coverage
Gap Up
KNTE
Kinnate Biopharma
1.7$27.46-0.9%$1.20 billionN/A0.00Increase in Short Interest
Vor Biopharma logo
VOR
Vor Biopharma
1.9$26.60-7.4%$1.06 billionN/A0.00
CNTB
Connect Biopharma Holdings Limited American Depositary Shares
1.7$16.99-1.5%$962.29 millionN/A0.00Analyst Report
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$24.17-0.5%$882.77 millionN/A0.00
FDMT
4D Molecular Therapeutics
1.3$31.32-5.4%$880.90 millionN/A0.00
Gracell Biotechnologies logo
GRCL
Gracell Biotechnologies
1.5$12.24-4.6%$839.21 millionN/A0.00Gap Up
Pharming Group logo
PHAR
Pharming Group
0.0$12.95-0.9%$827.27 millionN/A0.00
iTeos Therapeutics logo
ITOS
iTeos Therapeutics
1.9$22.32-5.8%$737.78 millionN/A0.00
FNCH
Finch Therapeutics Group
2.0$14.10-9.9%$730.28 millionN/A0.00Analyst Report
News Coverage
Gap Up
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$15.45-0.4%$630.05 millionN/A0.00
Inventiva logo
IVA
Inventiva
1.4$13.39-0.4%$517.26 millionN/A0.00News Coverage
Gap Down
SGTX
Sigilon Therapeutics
1.4$15.83-1.5%$506.09 millionN/A0.00Gap Up
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
1.7$10.80-3.9%$482.45 millionN/A0.00Gap Up
Landos Biopharma logo
LABP
Landos Biopharma
1.8$10.24-6.0%$435.28 millionN/A0.00Gap Up
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.0$16.45-4.0%$429.64 millionN/A0.00Gap Down
NexImmune logo
NEXI
NexImmune
2.0$18.40-0.2%$417.84 millionN/A0.00
Sensei Biotherapeutics logo
SNSE
Sensei Biotherapeutics
2.0$12.89-2.4%$403.76 millionN/A0.00Gap Down
Angion Biomedica logo
ANGN
Angion Biomedica
1.7$12.62-7.5%$400.10 millionN/A0.00Gap Up
PRTG
Portage Biotech
0.0$29.40-8.2%$355.24 millionN/A0.00
Unity Biotechnology logo
UBX
Unity Biotechnology
1.1$4.84-7.2%$283.89 millionN/A-2.57Gap Up
Kaleido Biosciences logo
KLDO
Kaleido Biosciences
1.8$6.09-1.3%$262.02 millionN/A-2.41
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$9.58-2.7%$245.04 millionN/A0.00
VINC
Vincerx Pharma
1.0$17.24-0.1%$240.80 millionN/A0.00Gap Down
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$9.25-6.8%$188.90 millionN/A0.00Increase in Short Interest
News Coverage
LBPH
Longboard Pharmaceuticals
1.9$10.21-0.8%$171.37 millionN/A0.00Quiet Period Expiration
GANX
Gain Therapeutics
1.7$13.60-2.7%$158.29 millionN/A0.00Analyst Report
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$21.22-3.4%$152.49 millionN/A0.00Gap Up
EVAX
Evaxion Biotech A/S
1.7$7.00-2.1%$131.51 millionN/A0.00
LGVN
Longeveron
0.3$6.26-0.5%$118.10 millionN/A0.00
CMMB
Chemomab Therapeutics
0.0$32.00-7.8%$80.60 millionN/A0.00News Coverage
UPC
Universe Pharmaceuticals
0.0$3.45-2.9%$77.21 millionN/A0.00News Coverage
VRDN
Viridian Therapeutics
1.7$15.04-1.9%$58.78 millionN/A0.00Decrease in Short Interest
Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.19-1.0%$52.17 millionN/A0.00
VIRI
Virios Therapeutics
1.3$5.59-0.2%$46.57 millionN/A0.00
VIRX
Viracta Therapeutics
1.7$7.65-1.3%$39.06 millionN/A0.00
VYNT
Vyant Bio
0.0$3.42-1.2%$38.08 millionN/A0.00
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.12-6.7%$34.28 millionN/A0.00
VLON
Vallon Pharmaceuticals
0.3$4.39-3.6%$29.90 millionN/A0.00
VRPX
Virpax Pharmaceuticals
0.3$4.04-5.4%$21.07 millionN/A0.00News Coverage
Gap Up
BCTX
BriaCell Therapeutics
0.0$2.87-8.7%$2.41 millionN/A0.00Gap Up
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.60-1.5%$0.00N/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.